EP3320912
Ónæmismeðferð sem byggir á indólamín 2,3-díoxýgenasa
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
17.4.2009EP published:
31.3.2021EP application number:
17194619.7
EP translation filed:
14.5.2021Grant published:
15.7.2021EPO information:
European Patent Register
Max expiry date:
16.4.2029Expiry date:
16.4.2026Next due date:
30.4.2026
Title:
INDOLEAMINE 2, 3-DIOXYGENASE BASED IMMUNOTHERAPY
Timeline
Today
17.4.2009EP application
31.3.2021EP Publication
14.5.2021Translation submitted
15.7.2021Registration published
16.4.2026Expires
Owner
Name:
IO BIOTECH ApSAddress:
c/o COBIS Ole Maaløes Vej 3, 2200 Copenhagen N, DK
Inventor
Name:
ANDERSEN, Mads HaldAddress:
2850 Nærum, DK
Name:
STRATEN, Per ThorAddress:
2650 Hvidovre, DK
Agent
Name:
Tego ehf.Address:
Pósthólf 8129, 128, Reykjavík,
Priority
Number:
200800565Date:
17.4.2008Country:
DK
Classification
Categories:
A61K 38/17, A61K 38/08, A61K 38/10, A61K 38/44, A61K 39/00, A61K 38/19, A61K 38/20, A61K 45/06, C12N 9/02
Annual fees
Number
Paid
Expires
Payer
Number: 13
Paid: 30.4.2021
Expires: 16.4.2022
Payer: Tego ehf.
Number: 14
Paid: 10.3.2022
Expires: 16.4.2023
Payer: Árnason Faktor ehf.
Number: 15
Paid: 8.3.2023
Expires: 16.4.2024
Payer: Árnason Faktor ehf.
Number: 16
Paid: 7.3.2024
Expires: 16.4.2025
Payer: Árnason Faktor ehf.
Number: 17
Paid: 14.3.2025
Expires: 16.4.2026
Payer: Árnason Faktor ehf.